Risedronate

• Osteoporosis
• Paget's Disease of Bone
• Glucocorticoid-Induced Osteoporosis
• Postmenopausal Bone Loss

Risedronate (brand names Actonel and Atelvia) is a nitrogen-containing bisphosphonate used to prevent and treat osteoporosis in postmenopausal women, increase bone mass in men with osteoporosis, manage glucocorticoid-induced bone loss, and treat Paget's disease of bone. Available in daily, weekly, and monthly tablet schedules and in a delayed-release form that simplifies administration relative to the immediate-release version, it reduces the relative risk of vertebral and nonvertebral fractures by roughly 40 to 50 percent in pivotal trials over three years. As one of the foundational antiresorptive agents, it has been in widespread use for over two decades and remains a cost-effective first-line option.

Mechanism of Action

Risedronate has high affinity for hydroxyapatite, the mineral component of bone, and concentrates at sites of active remodeling within hours of dosing. Once internalized by osteoclasts during the resorptive process, it inhibits farnesyl pyrophosphate synthase in the mevalonate pathway. The resulting failure to prenylate small GTPases (Rab, Rho, Rac) disrupts the osteoclast cytoskeleton and ruffled border, impairing resorptive activity and triggering apoptosis of osteoclasts. The net result is reduced bone turnover, preservation or improvement of bone mineral density (typically 3-6 percent gains at the spine over three years), and improved trabecular architecture as remodeling units complete without being replaced as quickly. Effects persist for months to years after discontinuation because the drug remains embedded in bone matrix and is slowly re-released as bone remodels around it; this property underlies the concept of a drug holiday after several years of therapy. The NIH bone health resource reviews the bisphosphonate class.

Clinical Use

Risedronate is a first-line option for osteoporosis treatment alongside alendronate and intravenous zoledronic acid. Ibandronate is also a bisphosphonate option but with weaker nonvertebral fracture reduction data and is generally not preferred for high-risk patients. For patients who cannot tolerate oral bisphosphonates due to gastrointestinal effects or who cannot follow the strict dosing requirements, options include zoledronic acid (annual IV infusion), denosumab (subcutaneous every 6 months), or anabolic agents such as teriparatide for severe disease defined by very low T-scores or multiple prior fractures. The duration of bisphosphonate therapy is now generally five years for oral agents (three for IV), followed by reassessment of fracture risk and consideration of a drug holiday in lower-risk patients (those who are no longer at very high fracture risk and have stable BMD). Higher-risk patients may continue therapy or switch to alternative agents. Glucocorticoid-induced bone loss is a particularly common indication, since chronic prednisone-equivalent doses of 5 mg or more for three months substantially raise fracture risk. The American College of Physicians guideline outlines current recommendations for screening, treatment, and duration. Our article on building stronger bones at any age covers lifestyle adjuncts including weight-bearing exercise, fall prevention, and adequate protein intake.

How to Take It

The immediate-release tablet must be taken first thing in the morning on a completely empty stomach with a full 6 to 8 ounces of plain water (no coffee, tea, juice, milk, or mineral water, all of which significantly impair absorption), and the patient must remain upright (sitting or standing) for at least 30 minutes without eating, drinking anything other than plain water, or taking other oral medications including supplements. The delayed-release Atelvia formulation is taken right after breakfast with at least 4 ounces of plain water, also followed by 30 minutes upright; this version is often easier for patients to fit into a daily routine because it does not require fasting. If a weekly dose is missed, take it the next morning and resume the original schedule on the usual weekly day; if a monthly dose is missed and the next dose is more than seven days away, take it as soon as remembered, then resume the original schedule. Do not double doses to make up for a missed one. Many patients find a reminder system (phone alarm, weekly pill box, calendar marking) essential for consistent adherence over years.

Monitoring and Follow-Up

Before starting, correct vitamin D deficiency (target 25-OH vitamin D above 30 ng/mL) and any hypocalcemia; verify adequate calcium intake of 1000-1200 mg daily through diet and supplements as needed, since bisphosphonates can precipitate symptomatic hypocalcemia in deficient patients. A baseline DXA scan establishes T-score and Z-score, and follow-up DXA is reasonable at one to two years to confirm response, with stable or improving BMD indicating success. Periodic measurement of serum calcium, creatinine, and 25-OH vitamin D is appropriate; our lab panels overview explains what these values mean. Bone turnover markers such as serum CTX or P1NP can be used to confirm pharmacologic effect within three to six months, although routine use is not required. Dental evaluation before starting is sensible for patients with poor oral health, planned major dental work, or other osteonecrosis risk factors. Reassess fracture risk at five years using DXA and FRAX scoring to determine whether continued therapy or a drug holiday is appropriate.

Special Populations

Risedronate is not recommended when creatinine clearance falls below 30 mL/min because of insufficient safety data and concern for accumulation. No adjustment is needed for hepatic impairment, since the drug is not hepatically metabolized. It is not used in premenopausal women planning pregnancy due to long bone retention (years to decades) and theoretical fetal risk from transplacental transfer, though human data are limited and reassuring in inadvertent exposures. It is not approved in pediatric patients outside specialized indications such as osteogenesis imperfecta managed by pediatric endocrinology. Older adults often benefit most from therapy but require careful attention to esophageal disorders, swallowing capacity, and the ability to remain upright for the required interval. Patients with achalasia, esophageal strictures, Barrett's esophagus, or who cannot stand or sit upright for 30 minutes should not take oral bisphosphonates and may be candidates for IV zoledronic acid or denosumab instead.

Drug Holidays, Sequence of Therapy, and Adjuncts

The concept of a bisphosphonate drug holiday emerged from concern about atypical femur fractures and osteonecrosis of the jaw, both of which appear to increase with cumulative bisphosphonate exposure beyond five years. Current expert opinion supports stopping oral bisphosphonates after five years (or IV zoledronic acid after three years) in patients whose fracture risk has stabilized in a lower range, with reassessment every one to three years using DXA, FRAX, and bone turnover markers. Higher-risk patients (history of vertebral fracture, T-score below -3.0 despite therapy, ongoing glucocorticoid use) should generally continue therapy for up to ten years or transition to alternative agents. Sequencing therapies has become an active area of practice: starting with an anabolic agent such as teriparatide, abaloparatide, or romosozumab for severe osteoporosis followed by a bisphosphonate to consolidate gains produces greater BMD improvement than starting with bisphosphonate alone. Denosumab, unlike bisphosphonates, has no residual skeletal effect after discontinuation; stopping denosumab without transitioning to a bisphosphonate produces rapid bone loss and increased vertebral fracture risk, so this transition must be planned carefully. Lifestyle interventions amplify drug benefit: weight-bearing exercise (walking, dancing, resistance training) maintains and modestly increases bone density and improves balance to reduce falls; smoking cessation; alcohol limitation to fewer than two drinks per day; and adequate dietary protein support bone health. Fall prevention is at least as important as bone density in older adults; environmental modifications, vision correction, review of fall-risk medications, and exercise programs targeting balance reduce fracture risk substantially, as covered in our fall prevention guide. Calcitonin salmon and raloxifene are alternative options for selected patients but are generally less effective than bisphosphonates for fracture risk reduction.

When to Contact Your Doctor

Call promptly for new or worsening retrosternal pain, painful swallowing (odynophagia), heartburn unresponsive to position changes, or any vomiting of blood, which may indicate esophageal injury or ulceration. Persistent thigh, hip, or groin pain (especially preceding a fall, often described as dull and present for weeks) can be a warning sign of an atypical femur fracture and warrants imaging. Jaw pain, loose teeth, non-healing dental sockets after extraction, or exposed bone after dental work can suggest osteonecrosis of the jaw and warrant evaluation by your physician and dentist. Severe musculoskeletal pain that develops at any point during therapy should be reported. Numbness or tingling around the mouth, muscle cramps, or palpitations may signal hypocalcemia and warrant a calcium check.

If you have been diagnosed with osteoporosis, are starting long-term steroid therapy, or want to review your fracture risk, contact us or schedule a visit.